(Irvine, CA.  April 24, 2019) – nRichDX Inc. is pleased to confirm that, under the direction of Ryan B. Corcoran, MD, PhD, Massachusetts General Hospital Cancer Center will participate in beta studies evaluating the performance of the nRichDX’s liquid biopsy sample prep platform, the Revolution System.  The studies will focus on the System’s ability to deliver greater target yields by combining larger volume processing with high recovery rates.  Dr. Corcoran’s lab has been influential in developing liquid biopsy diagnostics and specializes in the analysis of circulating tumor DNA (ctDNA).